467 related articles for article (PubMed ID: 34685488)
1. ERK: A Double-Edged Sword in Cancer. ERK-Dependent Apoptosis as a Potential Therapeutic Strategy for Cancer.
Sugiura R; Satoh R; Takasaki T
Cells; 2021 Sep; 10(10):. PubMed ID: 34685488
[TBL] [Abstract][Full Text] [Related]
2. Targeting ERK1/2 protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Apr; 142():151-168. PubMed ID: 30794926
[TBL] [Abstract][Full Text] [Related]
3. ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway.
Kidger AM; Sipthorp J; Cook SJ
Pharmacol Ther; 2018 Jul; 187():45-60. PubMed ID: 29454854
[TBL] [Abstract][Full Text] [Related]
4. Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells.
Oh YT; Deng J; Yue P; Sun SY
Sci Rep; 2016 May; 6():26803. PubMed ID: 27222248
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition.
Cagnol S; Rivard N
Oncogene; 2013 Jan; 32(5):564-76. PubMed ID: 22430215
[TBL] [Abstract][Full Text] [Related]
6. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
7. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
[TBL] [Abstract][Full Text] [Related]
8. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
Roberts PJ; Der CJ
Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
[TBL] [Abstract][Full Text] [Related]
10. Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy.
Wei F; Yan J; Tang D
Curr Med Chem; 2011; 18(35):5476-82. PubMed ID: 22087839
[TBL] [Abstract][Full Text] [Related]
11. NSC 95397 Suppresses Proliferation and Induces Apoptosis in Colon Cancer Cells through MKP-1 and the ERK1/2 Pathway.
Dubey NK; Peng BY; Lin CM; Wang PD; Wang JR; Chan CH; Wei HJ; Deng WP
Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29857489
[TBL] [Abstract][Full Text] [Related]
12. Spatiotemporal regulation of ERK2 by dual specificity phosphatases.
Caunt CJ; Armstrong SP; Rivers CA; Norman MR; McArdle CA
J Biol Chem; 2008 Sep; 283(39):26612-23. PubMed ID: 18650424
[TBL] [Abstract][Full Text] [Related]
13. Pro-apoptotic role of the MEK/ERK pathway in ursodeoxycholic acid-induced apoptosis in SNU601 gastric cancer cells.
Lim SC; Duong HQ; Parajuli KR; Han SI
Oncol Rep; 2012 Oct; 28(4):1429-34. PubMed ID: 22824956
[TBL] [Abstract][Full Text] [Related]
14. The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy.
Yu Z; Ye S; Hu G; Lv M; Tu Z; Zhou K; Li Q
Future Med Chem; 2015; 7(3):269-89. PubMed ID: 25826360
[TBL] [Abstract][Full Text] [Related]
15. AMP-activated protein kinase antagonizes pro-apoptotic extracellular signal-regulated kinase activation by inducing dual-specificity protein phosphatases in response to glucose deprivation in HCT116 carcinoma.
Kim MJ; Park IJ; Yun H; Kang I; Choe W; Kim SS; Ha J
J Biol Chem; 2010 May; 285(19):14617-27. PubMed ID: 20220132
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing.
Oh YT; Deng J; Yue P; Owonikoko TK; Khuri FR; Sun SY
Oncogene; 2016 Jan; 35(4):459-67. PubMed ID: 25867065
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
18. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.
Johnson GL; Stuhlmiller TJ; Angus SP; Zawistowski JS; Graves LM
Clin Cancer Res; 2014 May; 20(10):2516-22. PubMed ID: 24664307
[TBL] [Abstract][Full Text] [Related]
19. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
[TBL] [Abstract][Full Text] [Related]
20. Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells.
Saidak Z; Giacobbi AS; Louandre C; Sauzay C; Mammeri Y; Galmiche A
Cancer Lett; 2017 Apr; 392():1-8. PubMed ID: 28161506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
